Nepstar Going Private As Wider China Meltdown Creates Relisting Uncertainties
This article was originally published in PharmAsia News
Another U.S.-listed Chinese healthcare firm is going private on the heels of Mindray, Wuxi, and China Cord Blood. But the current severe turbulence in China’s stock markets could complicate the prospects of relisting for other companies that have already taken this route and may be looking at re-offering their shares.
You may also be interested in...
Biogen/Eisai’s US filing of aducanumab for Alzheimer’s has a ripple effect in China, where a leading biomedical researcher has publicly questioned data for the country’s first approved drug for the disease, GV971.
From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies, underscored by its early emergence from the global pandemic and focus on certain technologies, with Boehringer Ingelheim the latest to be attracted.
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.